XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Information
 9 Months Ended
Oct. 01, 2021
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. This segment structure reflects the financial information and reports used by the Company’s management, specifically its Chief Operating Decision Maker, to make decisions regarding the Company’s business, including resource allocations and performance assessments. This segment structure reflects the Company’s current operating focus in compliance with ASC 280, Segment Reporting. For purposes of segment reporting, intercompany sales between segments are not material.
The following table presents sales by product line (in thousands):
 Three Months EndedNine Months Ended
October 1,
2021		October 2,
2020		October 1,
2021		October 2,
2020
Segment sales by product line:
Medical
Cardio & Vascular$160,858 $124,596 $462,632 $432,885 
Cardiac & Neuromodulation106,543 72,909 334,700 252,404 
Advanced Surgical, Orthopedics & Portable Medical28,720 30,179 83,380 92,041 
Total Medical296,121 227,684 880,712 777,330 
Non-Medical9,453 8,258 27,352 27,153 
Total sales$305,574 $235,942 $908,064 $804,483 
The following table presents income for the Company’s reportable segments (in thousands):
 Three Months EndedNine Months Ended
October 1,
2021		October 2,
2020		October 1,
2021		October 2,
2020
Segment income:
Medical$52,347 $28,777 $164,311 $120,903 
Non-Medical2,016 1,214 5,374 4,894 
Total segment income54,363 29,991 169,685 125,797 
Unallocated operating income (expenses)(a)
(21,273)9,767 (62,637)(32,778)
Operating income33,090 39,758 107,048 93,019 
Unallocated expenses, net(9,911)(8,358)(28,113)(24,815)
Income before taxes$23,179 $31,400 $78,935 $68,204 
__________
(a) Unallocated operating income (expenses) for the three and nine months ended October 2, 2020 includes a net gain of $28.2 million related to a patent litigation judgment.